Back to Search
Start Over
Chronic treatment with resveratrol improves overactive bladder in obese mice via antioxidant activity.
- Source :
-
European journal of pharmacology [Eur J Pharmacol] 2016 Oct 05; Vol. 788, pp. 29-36. Date of Electronic Publication: 2016 Jun 15. - Publication Year :
- 2016
-
Abstract
- The objective of the present work was to evaluate whether oral intake with resveratrol ameliorates overactive bladder in high-fat fed mice. Male C57BL6 mice fed with standard chow or high-fat diet to induce obesity received a two-week therapy with resveratrol (100mg/kg, given as a daily gavage). Weight and metabolic profile, together with cystometry and in vitro bladder contractions were evaluated. Measurements of gp91phox and SOD1 mRNA expressions and reactive-oxygen species (ROS) in bladder tissues, and serum TBARS were performed. Obese mice exhibited increases in body weight and epididymal fat mass, which were significantly reduced by oral treatment with resveratrol. Cystometric study in obese mice showed increases in non-voiding contractions, post-voiding pressure and voiding frequency that were reversed by resveratrol treatment. Likewise, the in vitro bladder overactivity in response to electrical-field stimulation (80V, 1-32Hz) or carbachol (1nM to 10mM) were normalized by resveratrol. The gp91phox and SOD1 mRNA expressions in bladder tissues were markedly higher in obese mice compared with lean group. In addition, ROS levels in bladder tissues and serum lipid peroxidation (TBARS assay) were markedly higher in obese compared with lean mice, all of which were reduced by resveratrol treatment. In lean group, resveratrol had no effect in any parameter evaluated. Our results show that two-week therapy of obese mice with resveratrol reduces the systemic and bladder oxidative stress, and greatly ameliorated the cystometry alterations and in vitro bladder overactivity. Resveratrol treatment could be an option to prevent obesity-associated overactive bladder.<br /> (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Subjects :
- Administration, Oral
Animals
Anti-Obesity Agents administration & dosage
Anti-Obesity Agents therapeutic use
Antioxidants administration & dosage
Antioxidants therapeutic use
Body Weight drug effects
Diet, High-Fat adverse effects
Gene Expression Regulation, Enzymologic drug effects
Male
Membrane Glycoproteins genetics
Mice
Mice, Inbred C57BL
Muscle, Smooth drug effects
Muscle, Smooth metabolism
NADPH Oxidase 2
NADPH Oxidases genetics
Obesity etiology
Oxidative Stress drug effects
RNA, Messenger genetics
RNA, Messenger metabolism
Resveratrol
Stilbenes administration & dosage
Stilbenes therapeutic use
Superoxide Dismutase-1 genetics
Time Factors
Urinary Bladder drug effects
Urinary Bladder metabolism
Urinary Bladder, Overactive genetics
Urinary Bladder, Overactive metabolism
Anti-Obesity Agents pharmacology
Antioxidants pharmacology
Obesity complications
Stilbenes pharmacology
Urinary Bladder, Overactive complications
Urinary Bladder, Overactive drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0712
- Volume :
- 788
- Database :
- MEDLINE
- Journal :
- European journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 27316789
- Full Text :
- https://doi.org/10.1016/j.ejphar.2016.06.017